Zentiva

At Zentiva, we provide health and wellbeing for all generations

We develop, produce, and deliver high-quality, affordable medicines to more than 100 million people in over 30 countries across Europe and beyond. Our team of 5,000 unique talents share a commitment to the people who depend on our medicines every day.

Zentiva Expands into Biologics with the EU-Wide Launch of Its First Biosimilar

Launch marks Zentiva’s strategic entry into biosimilars and reinforces its mission to broaden patient access to high-quality biologic medicines across Europe.

Demonstrating accountability: Zentiva receives prestigious ESG Transparency Award 2025

Zentiva, a leading European generics pharmaceutical company, has received the esteemed ESG Transparency Award 2025 by the EUPD Group. This award recognises companies that excel in clarity, structure and transparency in their Environmental, Social and Governance (ESG) reporting.

Zentiva announces sale from Advent to GTCR

Zentiva, a leading European generics pharmaceutical company, Advent and GTCR – two leading global private equity investors – today announce the sale of Zentiva by Advent to GTCR.

Zentiva at CPHI Frankfurt 2025: Innovation, Growth and Trusted Partnerships 

Zentiva is pleased to announce its participation in CPHI Worldwide 2025, taking place from 28 to 30 October at Messe Frankfurt, Germany.

Zentiva joins UN Target Gender Equality Accelerator

Gender equality is not only a fundamental human right – it is also a powerful driver of business success. As a pan-European company, we have both the responsibility and the opportunity to lead in advancing gender equality across the continent and beyond.